Finance

Lists
Why is BBNX down 4,22%?
Dive Deeper
BBNX:NASDAQ
Beta Bionics Inc
USD 18,59
-4,22%
(-0,82) 1D
30 Sep., 10:36:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBNX...
Open
USD 19,22
High
USD 19,22
Low
USD 18,45
Mkt. cap
978,46 m
Avg. vol.
1,36 m
Volume
124,15 k
52-wk high
USD 32,71
52-wk low
USD 8,80
EPS
-USD 1,65
Shares outstanding
52,64 m
No. of employees
422
Open
USD 19,22
High
USD 19,22
Low
USD 18,45
Mkt. cap
978,46 m
Avg. vol.
1,36 m
Volume
124,15 k
52-wk high
USD 32,71
52-wk low
USD 8,80
EPS
-USD 1,65
Shares outstanding
52,64 m
No. of employees
422
News stories
From web sources and news partners
About Beta Bionics Inc
CEO-
Employees422
Founded2015
HeadquartersIrvine, Kalifornië, Verenigde State van Amerika
SectorMedical device
Websitebetabionics.com
Analyst ratings
Based on 13 analysts giving stock ratings to BBNX in the past 3 months
Buy
Buy
9
Hold
4
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for BBNX in the last 3 months.
Highest
Current USD 18,59
USD 30,40 (+63,53%)
Average
USD 23,20 (+24,80%)
Lowest
USD 16,00 (-13,93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Richard Newitter
Truist Financial
Buy
Reiterated
USD 28,00
+50,6%
09/24/2026
Larry Biegelsen
Wells Fargo
Buy
Initiated
USD 28,00
+50,6%
09/23/2026
Frank Takkinen
Lake Street
Buy
Reiterated
USD 25,00
+34,5%
09/22/2026
Mike Kratky
Leerink Partners
Buy
Reiterated
USD 27,00
+45,2%
09/17/2026
Jonathan Block
Stifel Nicolaus
Buy
Maintained
USD 22,00
+18,3%
09/15/2026
Jeff Johnson
Robert W. Baird
Hold
Maintained
USD 16,00
-13,9%
09/15/2026
Patrick Wood
UBS
Buy
Maintained
USD 25,00
+34,5%
09/15/2026
Travis Steed
Bank of America Securities
Hold
Reiterated
USD 20,00
+7,6%
09/14/2026
Mathew Blackman
TD Cowen
Hold
Maintained
USD 18,00
-3,2%
09/14/2026
Steven Lichtman
William Blair
Hold
Maintained
-
-
09/14/2026
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Reiterated
USD 30,40
+63,5%
07/30/2026
Matthew O'Brien
Piper Sandler
Buy
Reiterated
USD 20,00
+7,6%
07/30/2026
Danielle Antalffy
UBS
Buy
Initiated
USD 22,00
+18,3%
07/28/2026
David Roman
Goldman Sachs
Buy
Reiterated
USD 19,00
+2,2%
07/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
27,25 m
32,12 m
27,63 m
32,01 m
Cost of goods sold
12,13 m
13,18 m
11,19 m
13,11 m
Cost of revenue
12,13 m
13,18 m
11,19 m
13,11 m
Research and development expenses
8,20 m
10,13 m
10,36 m
10,24 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
23,97 m
24,94 m
30,35 m
34,24 m
Operating expense
32,16 m
35,07 m
40,71 m
44,48 m
Total operating expenses
44,30 m
48,24 m
51,90 m
57,59 m
Operating income
-17,04 m
-16,12 m
-24,27 m
-25,58 m
Other non operating income
1,00 k
-
-
-2,00 k
EBT including unusual items
-14,21 m
-13,47 m
-21,90 m
-23,40 m
EBT excluding unusual items
-14,21 m
-13,47 m
-21,90 m
-23,40 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14,21 m
-13,47 m
-21,90 m
-23,40 m
Net profit margin
-52,14%
-41,92%
-79,25%
-73,10%
Earnings per share
-0,33
-0,19
-0,36
-0,36
Interest and investment income
2,83 m
2,66 m
2,38 m
2,18 m
Interest expense
-
-
-
-
Net interest expenses
2,83 m
2,66 m
2,38 m
2,18 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-16,66 m
-15,59 m
-23,69 m
-24,87 m
Gain or loss from assets sale
-
31,00 k
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme